Who Paid My Doc
Patrick Culligan
Obstetrics & Gynecology Morristown, NJ Medical Doctor
NPI 1497727721 CMS profile 67303
435 South St, Suite 370, Morristown, NJ 07960
General payments
$92,805
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Patrick Culligan of Morristown, NJ is reported in the CMS Open Payments database as having received $92,805 across 177 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 99th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $19,264 | 19 | |
| 2024 | General | $25,817 | 33 | |
| 2023 | General | $6,839 | 13 | |
| 2022 | General | $26,194 | 43 | |
| 2021 | General | $2,354 | 25 | |
| 2020 | General | $2,591 | 11 | |
| 2019 | General | $9,748 | 33 |
Beside peers
- Patrick Culligan
- Obstetrics & Gynecology median
- Middle half of Obstetrics & Gynecology
- National median
In program year 2025, general payments to Patrick Culligan were reported at $19,264. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.
Show as a table
| Year | Patrick Culligan | Obstetrics & Gynecology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $9,748 | $172 | $62–$391 | $163 |
| 2020 | $2,591 | $94 | $36–$222 | $114 |
| 2021 | $2,354 | $136 | $42–$369 | $132 |
| 2022 | $26,194 | $160 | $50–$433 | $149 |
| 2023 | $6,839 | $169 | $56–$423 | $160 |
| 2024 | $25,817 | $152 | $50–$371 | $164 |
| 2025 | $19,264 | $158 | $51–$401 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 10 drugsPart D claims
738
Drug cost
$259,920
Branded share of claims
65.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Myrbetriq Mirabegron | Brand | 213 | $186,562 | |
| Estradiol | Generic | 214 | $18,942 | |
| Estring Estradiol | Brand | 30 | $15,567 | |
| Gemtesa Vibegron | Brand | 13 | $13,523 | |
| Mirabegron Er Mirabegron | Brand | 19 | $10,598 | |
| Yuvafem Estradiol | Brand | 44 | $7,949 | |
| Premarin Estrogens, Conjugated | Brand | 13 | $5,648 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 106 | $741 | |
| Ciprofloxacin Hcl | Generic | 42 | $266 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 44 | $125 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 40 billing codesPaid by Medicare
$241,848
Medicare patients
474
Services billed
3,720
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 74% | |
| Arthritis | 59% | |
| Osteoporosis | 35% | |
| Diabetes | 26% | |
| Ischemic heart disease | 22% | |
| Cancer | 20% | |
| Depression | 20% | |
| Atrial fibrillation | 13% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, onabotulinumtoxina, 1 unit J0585 | Office | 12 | 2,000 | $9,960 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
177 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Obstetrics & Gynecology in New Jersey
Jennifer Ashton
Obstetrics & Gynecology · Englewood, NJ
Geoffrey Bowers
Obstetrics & Gynecology · Voorhees, NJ
Neha Deshpande
Obstetrics & Gynecology · Plainsboro, NJ
Justin Chura
Obstetrics & Gynecology · Swedesboro, NJ
Aiman Shilad
Obstetrics & Gynecology · Paterson, NJ
Dipak Delvadia
Obstetrics & Gynecology · Cherry Hill, NJ
Related records
Obstetrics & Gynecology in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Obstetrics & Gynecology
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.